Eli Lilly’s October 2024 research-only agreement with Peptron granted non-exclusive rights to evaluate SmartDepot, an ultrasonic spray-dried PLGA microsphere platform for sustained peptide release, without commercial manufacturing or sales rights. Nearly two years later, no binding technology-transfer or licensing deal has been announced, while Lilly separately partnered with Camurus in June 2026 for its competing FluidCrystal platform targeting long-acting incretins. The ongoing evaluation lacks public milestones or signals of imminent expansion, leaving little time before the October 7 resolution date. Traders therefore price the “No” outcome at 87.5% implied probability, reflecting the absence of confirmed progress toward a commercial agreement.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated13% chance
$11,264 Vol.
$11,264 Vol.
Oct 7, 2026
13% chance
$11,264 Vol.
$11,264 Vol.
Oct 7, 2026
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s October 2024 research-only agreement with Peptron granted non-exclusive rights to evaluate SmartDepot, an ultrasonic spray-dried PLGA microsphere platform for sustained peptide release, without commercial manufacturing or sales rights. Nearly two years later, no binding technology-transfer or licensing deal has been announced, while Lilly separately partnered with Camurus in June 2026 for its competing FluidCrystal platform targeting long-acting incretins. The ongoing evaluation lacks public milestones or signals of imminent expansion, leaving little time before the October 7 resolution date. Traders therefore price the “No” outcome at 87.5% implied probability, reflecting the absence of confirmed progress toward a commercial agreement.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Market Opened: May 5, 2026, 8:02 PM ET
Volume
$11,264End Date
Oct 7, 2026Market Opened
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s October 2024 research-only agreement with Peptron granted non-exclusive rights to evaluate SmartDepot, an ultrasonic spray-dried PLGA microsphere platform for sustained peptide release, without commercial manufacturing or sales rights. Nearly two years later, no binding technology-transfer or licensing deal has been announced, while Lilly separately partnered with Camurus in June 2026 for its competing FluidCrystal platform targeting long-acting incretins. The ongoing evaluation lacks public milestones or signals of imminent expansion, leaving little time before the October 7 resolution date. Traders therefore price the “No” outcome at 87.5% implied probability, reflecting the absence of confirmed progress toward a commercial agreement.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Volume
$11,264End Date
Oct 7, 2026Market Opened
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...Eli Lilly’s October 2024 research-only agreement with Peptron granted non-exclusive rights to evaluate SmartDepot, an ultrasonic spray-dried PLGA microsphere platform for sustained peptide release, without commercial manufacturing or sales rights. Nearly two years later, no binding technology-transfer or licensing deal has been announced, while Lilly separately partnered with Camurus in June 2026 for its competing FluidCrystal platform targeting long-acting incretins. The ongoing evaluation lacks public milestones or signals of imminent expansion, leaving little time before the October 7 resolution date. Traders therefore price the “No” outcome at 87.5% implied probability, reflecting the absence of confirmed progress toward a commercial agreement.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated
Beware of external links.
Beware of external links.
Frequently Asked Questions